The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can also exhibit efficacy in HR-competent cancers, by amplifying the...

Full description

Bibliographic Details
Main Authors: Zhaozhen Wu, Pengfei Cui, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Shixue Chen, Ziwei Huang, Xuan Zheng, Di Huang, Yi Hu
Format: Article
Language:English
Published: SAGE Publishing 2021-02-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/1179554921996288

Internet

https://doi.org/10.1177/1179554921996288

Similar Items